Marianne Jansson
61 – 70 of 72
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2008
-
Mark
Suppression of HIV replication in vitro by CpG and CpG conjugated to the non toxic B subunit of cholera toxin
(
- Contribution to journal › Article
-
Mark
Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-I variants emerging during AIDS progression
(
- Contribution to journal › Article
-
Mark
Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge.
(
- Contribution to journal › Article
- 2005
-
Mark
Coreceptor usage of primary HIV type 1 isolates obtained from different lymph node subsets
(
- Contribution to journal › Article
-
Mark
Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation
(
- Contribution to journal › Article
-
Mark
Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency.
(
- Contribution to journal › Article
- 2004
-
Mark
Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype.
(
- Contribution to journal › Article